X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GSK PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GSK PHARMA SUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 29.0 48.9 59.3% View Chart
P/BV x 2.4 9.7 24.9% View Chart
Dividend Yield % 0.5 1.6 32.0%  

Financials

 SUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
GSK PHARMA
Mar-19
SUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7013,595 19.5%   
Low Rs4331,253 34.6%   
Sales per share (Unadj.) Rs110.4184.7 59.8%  
Earnings per share (Unadj.) Rs11.026.3 41.8%  
Cash flow per share (Unadj.) Rs17.229.2 59.1%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.40.8 42.8%  
Book value per share (Unadj.) Rs158.8126.3 125.7%  
Shares outstanding (eoy) m2,399.26169.40 1,416.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.113.1 39.1%   
Avg P/E ratio x51.692.2 56.0%  
P/CF ratio (eoy) x32.983.1 39.6%  
Price / Book Value ratio x3.619.2 18.6%  
Dividend payout %18.276.1 24.0%   
Avg Mkt Cap Rs m1,360,021410,626 331.2%   
No. of employees `00017.85.0 358.6%   
Total wages/salary Rs m53,6715,372 999.1%   
Avg. sales/employee Rs Th14,890.96,306.7 236.1%   
Avg. wages/employee Rs Th3,017.11,083.1 278.6%   
Avg. net profit/employee Rs Th1,480.6898.0 164.9%   
INCOME DATA
Net Sales Rs m264,89531,281 846.8%  
Other income Rs m8,3881,023 819.8%   
Total revenues Rs m273,28232,304 846.0%   
Gross profit Rs m56,0816,009 933.3%  
Depreciation Rs m14,998486 3,086.1%   
Interest Rs m5,1766 86,261.7%   
Profit before tax Rs m44,2956,540 677.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505287 -3,311.8%   
Tax Rs m8,4522,373 356.2%   
Profit after tax Rs m26,3384,454 591.3%  
Gross profit margin %21.219.2 110.2%  
Effective tax rate %19.136.3 52.6%   
Net profit margin %9.914.2 69.8%  
BALANCE SHEET DATA
Current assets Rs m316,35920,061 1,577.0%   
Current liabilities Rs m198,64314,543 1,365.9%   
Net working cap to sales %44.417.6 251.9%  
Current ratio x1.61.4 115.5%  
Inventory Days Days9557 167.0%  
Debtors Days Days10814 765.9%  
Net fixed assets Rs m213,17814,343 1,486.3%   
Share capital Rs m2,3991,694 141.6%   
"Free" reserves Rs m378,60619,704 1,921.4%   
Net worth Rs m381,00621,398 1,780.5%   
Long term debt Rs m17,7212 886,045.0%   
Total assets Rs m643,02839,113 1,644.0%  
Interest coverage x9.61,091.0 0.9%   
Debt to equity ratio x00 49,762.6%  
Sales to assets ratio x0.40.8 51.5%   
Return on assets %4.911.4 43.0%  
Return on equity %6.920.8 33.2%  
Return on capital %10.031.9 31.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,816534 7,643.5%   
Fx outflow Rs m30,1437,091 425.1%   
Net fx Rs m10,673-6,557 -162.8%   
CASH FLOW
From Operations Rs m39,0723,994 978.3%  
From Investments Rs m-33,708-1,433 2,351.6%  
From Financial Activity Rs m-15,393-3,584 429.5%  
Net Cashflow Rs m-7,359-1,023 719.2%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.1 10.2 50.3%  
FIIs % 23.0 23.8 96.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 15.4 53.9%  
Shareholders   133,026 102,036 130.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views on News

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 24, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - BIOCON COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS